how-immune-checkpoint-inhibitors-can-induce-diabetes

In a Q&A, Yale endocrinologist Ana Luisa Perdigoto examines how immune checkpoint inhibitors can trigger diabetes, identifies which patients might be at greater risk, and explains how her research aims to avert and manage this transformative condition.


Leave a Reply

Your email address will not be published. Required fields are marked *

Share This